home  syndax home about us back about us leadership board of directors scientific advisory board vision mission and values science back pipeline entinostat clinical trials publications access to investigational therapies investors collaboration career opportunities contact us contact us reimagining cancer treatment at syndax we are determined to realize a future in which people with cancer live longer and better than ever before search questions find answers what is entinostatwhat types of cancer is syndax addressingwhat clinical trials is syndax currently conductingwho is on the leadership team at syndaxwhere can i see your product pipelinewhat is the vision of syndaxis syndax hiringhow can my organization collaborate with syndax entinostat pipeline leadership publications  preclinical results support entinostat’s role in targeting the tumor microenvironment to enhance immune checkpoint therapy  syndax prices public offering of common stock  syndax announces proposed public offering of common stock  syndax announces results from phase  encore  trial of entinostat in combination with keytruda® pembrolizumab for the treatment of advanced melanoma pipeline  syndax home about us back about us leadership board of directors scientific advisory board vision mission and values science back pipeline entinostat clinical trials publications access to investigational therapies investors collaboration career opportunities contact us contact us pipelinepipeline entinostat clinical trials publications access to investigational therapies     syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications entinostat entinostat is our oral small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells potentially enhancing the body’s immune response to tumors the favorable safety profile of entinostat has been demonstrated in clinical trials in more than  cancer patients sndx sndx is a high affinity antibody targeting the colony stimulating factor  receptor csfr it has shown evidence of antitumor and antimetastatic efficacy through its ability to limit the number and activity of immunosuppressive cells such as tumor associated macrophages   entinostat clinical trials publications collaboration syndax pharmaceuticals inc sndxo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile syndax pharmaceuticals inc sndxo related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse sndxo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description syndax pharmaceuticals inc incorporated on october   is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications the company’s product candidate entinostat which was granted breakthrough therapy designation by the fda following positive results from its phase iib clinical trial encore  is being evaluated in a phase iii clinical trial for advanced hormone receptor positive breast cancer it is developing entinostat which has direct effects on both cancer cells and immune regulatory cells and sndx an anticsfr monoclonal antibody to enhance the bodys immune response on tumors that have shown sensitivity to immunotherapy entinostat is being evaluated as a combination therapeutic in phase ibii clinical trials with merck  co inc for nonsmall cell lung cancer and melanoma with genentech inc for tnbc and with pfizer inc and merck kgaa darmstadt germany for ovarian cancerentinostat is a class specific histone deacetylase hdac inhibitor which can directly reduce both the number and activity of myeloidderived suppressor cells mdscs and regulatory t cells tregs while sparing the cytotoxic t cells as of march   the company was evaluating entinostat in combination with keytruda pembrolizumab in a phase ibii clinical trial encore  for nonsmall cell lung cancer nsclc and melanoma as of march   the company had not generated any product revenues » full overview of sndxo company address syndax pharmaceuticals inc  totten pond rd ste waltham   ma    p f  company web links home page officers  directors name compensation dennis podlesak  michael metzger  briggs morrison  richard shea  michael meyers  » more officers  directors syndax pharmaceuticals inc news briefsyndax prices public offering of common stock may   briefsyndax pharma to offer common stock in public offering may   briefsyndax announces results from phase  encore  trial of entinostat in combination with keytruda may   briefsyndax pharmaceuticals announces advancement of encore  may   briefsyndax pharmaceuticals q loss per share  may   » more sndxo news related topics stocksstock screenerhealthcarepharmaceuticals syndax pharmaceuticals inc private company information  bloomberg july    pm et biotechnology company overview of syndax pharmaceuticals inc snapshot people company overview syndax pharmaceuticals inc a clinical stage biopharmaceutical company focuses on the development and commercialization of therapies for various cancer indications the company’s lead product candidate is entinostat which is in phase iii clinical trial for the treatment of hormone receptor positive human epidermal growth factor receptor  negative and breast cancer and phase b clinical trial it also develops sndx an immunoglobulin g subclass  isotype that binds to the ligand binding domain of csfr blocking the binding and consequent activation by natural ligands interleukin and colony stimulating factor and disrupting tumorassociated macrophages activity syndax pha syndax pharmaceuticals inc a clinical stage biopharmaceutical company focuses on the development and commercialization of therapies for various cancer indications the company’s lead product candidate is entinostat which is in phase iii clinical trial for the treatment of hormone receptor positive human epidermal growth factor receptor  negative and breast cancer and phase b clinical trial it also develops sndx an immunoglobulin g subclass  isotype that binds to the ligand binding domain of csfr blocking the binding and consequent activation by natural ligands interleukin and colony stimulating factor and disrupting tumorassociated macrophages activity syndax pharmaceuticals inc has clinical collaborations with msd international gmbh genentech and merck kgaa and pfizer collaborative research and development agreement with national cancer institute and license agreement with kyowa hakko kirin co ltd the company was founded in  and is headquartered in waltham massachusetts detailed description building dfloor  gatehouse drivewaltham ma united statesfounded in  employees phone  fax  wwwsyndaxcom key executives for syndax pharmaceuticals inc dr briggs w morrison md chief executive officer and director age  total annual compensation k mr michael a metzger mba president and chief operating officer age  total annual compensation k dr michael l meyers md phd chief medical officer and senior vice president age  total annual compensation k compensation as of fiscal year  syndax pharmaceuticals inc key developments syndax pharmaceuticals inc announces the publication of a preclinical report jul   syndax pharmaceuticals inc announced the publication of a preclinical report demonstrating that entinostat syndaxs oral classi histone deacetylase inhibitor enhances the antitumor effect of pd programmed death receptor blockade through the inhibition of myeloid derived suppressor cells mdscs researchers tested the effect of combining entinostat with an antipd monoclonal antibody that enhances the t cellmediated antitumor immune response the studies were conducted in two mouse models of renal cell carcinoma and lung cancer and included a series of in vitro experiments aimed at characterizing the effects of this combined treatment on the myeloid derived suppressor cells mdscs a highly immunosuppressive population of tumor infiltrating immature myeloid cells the results indicated that entinostat has an inhibitory effect on mdsc immunosuppressive function both in vivo and in vitro which results in enhanced antitumor activity of the combination syndax pharmaceuticals inc announces results from phase  encore  trial of entinostat in combination with keytruda for the treatment of advanced melanoma may   syndax pharmaceuticals inc announced results from the melanoma cohort of the ongoing phase  encore  trial of entinostat in combination with keytruda pembrolizumab mercks antipd programmed death receptor therapy which will be presented at the american society of clinical oncology asco annual meeting being held june   in chicago illinois encore  nct is a phase b trial evaluating the efficacy and safety of entinostat in combination with keytruda in melanoma patients whose disease had progressed despite prior treatment with antipdpdl therapies responses were seen both in patients who had as well as those who had not received prior treatment with yervoy® ipilimumab in combination with an antipd therapy either opdivo® nivolumab or keytruda of note  patient with a confirmed pr converted from a pdl negative noninflamed gene signature in a pretreatment tumor biopsy to pdl positive inflamed gene signature posttreatment with the entinostatkeytruda combination correlative analyses of peripheral blood and tumor tissue biomarkers across the entire patient cohort are ongoing the combination of entinostat and keytruda also appears to have a manageable toxicity profile with  patients having a treatment emergent adverse event with severity of grade   and with  patient discontinuing treatment due to an adverse event transaminitis that was deemed to be likely related to keytruda syndax pharmaceuticals to present data from melanoma study at  asco annual meeting may   syndax pharmaceuticals inc has announced that it will present results from the melanoma cohort of the ongoing phase ii encore  trial of entinostat in combination with keytruda pembrolizumab mercks antipd programmed death receptor therapy at the american society of clinical oncology or asco annual meeting in chicago illinois the company recently reported that the first cohort of  melanoma patients who had progressed on or after prior immune checkpoint inhibitor therapy in encore  met the prespecified objective response criteria with a minimum of  patients demonstrating a confirmed or unconfirmed objective response to advance into the second stage of the trial data from the first cohort of patients indicate that  patients achieved an objective response orr by irrecist criteria  patients had a confirmed response  patient had an unconfirmed response  orr  ci    of the  responders  patients had stable disease sd and  patients had progressive disease pd as best response to their prior antipd therapy prior to progressing with a median duration on prior antipd therapy of  months range  three patients remain on treatment without progression as of the data cutoff  with a partial response pr and  with sd similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact syndax pharmaceuticals inc please visit wwwsyndaxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one home  syndax home about us back about us leadership board of directors scientific advisory board vision mission and values science back pipeline entinostat clinical trials publications access to investigational therapies investors collaboration career opportunities contact us contact us reimagining cancer treatment at syndax we are determined to realize a future in which people with cancer live longer and better than ever before search questions find answers what is entinostatwhat types of cancer is syndax addressingwhat clinical trials is syndax currently conductingwho is on the leadership team at syndaxwhere can i see your product pipelinewhat is the vision of syndaxis syndax hiringhow can my organization collaborate with syndax entinostat pipeline leadership publications  preclinical results support entinostat’s role in targeting the tumor microenvironment to enhance immune checkpoint therapy  syndax prices public offering of common stock  syndax announces proposed public offering of common stock  syndax announces results from phase  encore  trial of entinostat in combination with keytruda® pembrolizumab for the treatment of advanced melanoma scientific advisory board  syndax home about us back about us leadership board of directors scientific advisory board vision mission and values science back pipeline entinostat clinical trials publications access to investigational therapies investors collaboration career opportunities contact us contact us scientific advisory boardabout us leadership board of directors scientific advisory board vision mission and values     ronald m evans phd ronald m evans phd sab chair and syndax cofounder is a professor in the gene expression laboratory at the salk institute for biological studies a howard hughes medical institute investigator and holds the march of dimes chair in developmental and molecular biology at the salk institute dr evans received his phd in microbiology and immunology and undergraduate degree from the university of california los angeles and conducted his postdoctoral research at rockefeller university dr evans is known for his work on nuclear receptors the discovery of a nuclear receptor superfamily and a unified the mechanism of hormone signaling hormonereceptor combinations help to control sugar salt calcium and fat metabolism and are primary targets in the treatment of breast cancer prostate cancer and leukemia osteoporosis chronic inflammation and asthma as founder of ligand pharmaceuticals his work led to the development of panretin® targretin® for the treatment of leukemia and lasofoxifene for the treatment of osteoporosis he was cofounder of xceptor therapeutics whose platform targeting orphan nuclear receptors for the treatment of metabolic diseases was acquired by exelixis in  he was a consultant for the development of aragon arn and seragon arn for prostate and breast cancer respectively he is the recipient of multiple awards including the albert lasker award  the wolf prize israel  and a member of the national academy of sciences and the institute of medicine julie r brahmer md msc julie r brahmer md msc is director of the thoracic oncology program and associate professor of oncology at the sidney kimmel comprehensive cancer center at johns hopkins as well as interim director of the johns hopkins kimmel cancer center at bayview in addition she serves as coprincipal investigator on the johns hopkins’ nci national clinical trials network nctn program grant and helps direct all oncology cooperative group activities on the johns hopkins campuses dr brahmer received her medical degree from the university of nebraska medical center college of medicine completed her residency at the university of utah and oncology fellowship at johns hopkins dr brahmer has been an advisor to syndax since december  dr brahmer is committed to the research and development of immunebased therapies in the treatment of lung cancer and other cancers such as mesothelioma she was principal investigator of the trials that led to the fda approval of the first immunotherapy option in lung cancer nivolumab as a result of her work she was named the march  lungevity hero and in november  received the dr thierry jahan “a breath away from the cure” award dr brahmer serves on the american society of clinical oncology and the eastern cooperative oncology group thoracic committee and cancer prevention steering committee and the scientific executive committee of free to breathe where she is also a founding board member she also serves on the medical advisory board of the lung cancer research foundation and lungevity lisa m coussens phd dr coussens is chair of the department of cell developmental  cancer biology and associate director for basic research in the knight cancer institute at oregon health  sciences university and holds the hildegard lamfrom chair in basic science dr coussens has been an advisor to syndax since january  dr coussens’ research is focused on revealing the role that normal immune cells play in regulating cancer development her lab reported that subsets of normal immune cells are coopted by early tumors to support ongoing cancer development and subsequently regulate tumor cell response to cytotoxic therapies her research identified critical immuneregulated pathways that can be targeted therapeutically to block or slow cancer development dr coussens and colleagues are conducting multicenter clinical trials evaluating novel immune cellantagonists in combination with chemotherapy in women with metastatic triple negative breast cancer pancreas cancer and head  neck squamous cancers in recognition of her research contributions to studying underlying mechanisms of cancer development dr coussens was awarded a v foundation scholar award  the gertrude b elion award  two era of hope scholar awards   the aacrwomen in cancer research charlotte friend memorial lectureship  and the th rosalind e franklin award from the nci  joseph paul eder md joseph paul eder md is director of the early drug development program and assistant director of experimental therapeutics at yale cancer center previously dr eder was the medical science director for astrazeneca’s boston site and prior to that he was clinical director of the dana farber cancer institute general cancer research center dr eder had also been the clinical director of the experimental therapeutics program for the danafarberharvard cancer center and was appointed principal clinical investigator of the harvard uo phase i program uniting the clinical efforts of the danafarber cancer institute brigham  women’s hospital massachusetts general hospital and beth israel deaconess medical center dr eder is a graduate of georgetown university school of medicine where he did a medical residency he did fellowships in medical oncology at georgetown and the danafarber cancer institute and a fellowship in hematologyoncology at beth israel hospital dr eder has been an advisor to syndax since january  dr eder is a leader in drug development and clinical research and has conducted studies in a variety of topics including high dose chemotherapy the modulation reversal of drug resistance growth factors vaccines novel agents analogue development signal transduction pathway inhibitors cell cycle inhibitors and the therapeutic use of antiangiogenesis agents he has served on scientific committees of the aacr and the international symposium on drug development rachel humphrey md rachel humphrey md is currently chief medical officer at cytomx an oncologyfocused biopharmaceutical company pioneering a novel class of antibody therapeutics based on its probody platform previously dr humphrey has held positions as vice president and head of immunooncology both at eli lilly and at astrazeneca and prior to that was vice president of product development at bristolmyers squibb bms dr humphrey received her medical degree from case western reserve university after completing her undergraduate degree at harvard university trained in internal medicine at the johns hopkins hospital and began her oncology career as a fellow and staff physician at the national cancer institute dr humphrey has been an advisor to syndax since november  dr humphrey is a leading oncology drug developer with significant achievements in the field of immunoncology and targeted therapy at bms she led all aspects of the early and latestage clinical development submission of global biologics license applications and global launch of the first fdaapproved immune checkpoint inhibitor yervoy® ipilimumab at bayer dr humphrey supervised all aspects of the early and latestage clinical development of nexavar® sorafenib for the treatment of renal cell carcinoma samir khleif md samir khleif md is the director of the georgia cancer center at augusta university where he has established a comprehensive immunooncology program that connects basic research discovery to clinical trials with highly integrated translational elements he is a georgia research alliance distinguished cancer scientist and clinician professor of medicine biochemistry cancer biology and graduate studies and director of the immunoncology and immunotherapeutic program previously dr khleif served as chief of the cancer vaccine section at the national cancer institute nci and professor of medicine at uniformed services university of the health sciences during his tenure at nci dr khleif was also detailed to serve for four years as the director general and ceo of the king hussein cancer center in amman expanding and strengthening the clinical operations and building that institution into a national comprehensive cancer center of excellence he also served as a special assistant to the fda commissioner from  where he led the fda critical path for oncology designed to restructure the oncology drug development process he received his medical degree from the university of amman in amman jordon and completed his residency at the medical college of ohio dr khleif has been an advisor to syndax since december  dr khleif’s research group focuses on the development of novel immune therapies and cancer vaccines and rational designs for combination immune therapy based on understanding the molecular mechanisms of the interaction between cancer and the immune system including cancerinduced immune suppression he has designed and served as a principal investigator of more than  immunooncology clinical trials testing novel immuneoncology approaches as single agents or in combination eg vaccines cpi or ido inhibitors his team designed and conducted some of the first cancer vaccine clinical trials and they are currently developing novel combination approaches to enhance antitumor effects dr khleif serves on the board of the society of immune therapy of cancer and he is a member of the national cancer policy forum of the national academy of medicine where he leads the immunotherapy task force dr khleif is the chair or member of many national committees on immunooncology and cancer research he is the recipient of many awards including the nci director gold star award and the public health service commendation medal hope s rugo md hope s rugo md is professor of medicine in the division of hematology and oncology at the university of california san francisco ucsf and director of breast cancer and clinical trial education at the ucsf helen diller family comprehensive cancer center dr rugo received her medical degree from the university of pennsylvania school of medicine after finishing an undergraduate program at tufts university she completed both a residency in internal medicine and fellowship in hematology and oncology at ucsf followed by a year postdoctoral fellowship in immunology at stanford university dr rugo has been an advisor to syndax since november  dr rugo is an investigator in the national multicenter ispy trial and is the principal investigator of multiple clinical trials researching novel therapies for advanced breast cancer immune modulation to restore chemotherapy sensitivity and the evaluation of circulating cells as novel markers of response and resistance to therapy neoadjuvant therapy and supportive care she has published many peerreviewed papers and has given presentations on a variety of breast cancer and supportive carerelated topics dr rugo is a member of the alliance breast core committee and the translational breast cancer research consortium is the ucsf representative to the national comprehensive cancer network guidelines committee and serves on several committees for the american society of clinical oncology she is one of three recipients of a komen promise award and received the cancer care physician of the year award in  george w sledge jr md george w sledge jr md has served as a member of our scientific advisory board since may  and served as a member of our board of directors from january  until his transition to the scientific advisory board since january  dr sledge has been professor and chief of medical oncology at stanford university medical center dr sledge served as a codirector of the breast cancer program at the indiana university simon cancer center from  to  and was a professor of medicine and pathology at the indiana university school of medicine from  to  from  to  dr sledge served as the president of the american society of clinical oncology a professional organization representing oncologists dr sledge is currently associate editor of jama oncology and has served as a member of the external advisory committee for the cancer genome atlas project chairman of the breast committee of the eastern cooperative oncology group chairman of the education committee of the american society of clinical oncology a member of the department of defense breast cancer research program’s integration panel and a member of the food and drug administration’s oncology drug advisory committee and the nci’s clinical trials advisory committee dr sledge received a ba from the university of wisconsin and an md from tulane university jedd d wolchok md phd jedd d wolchok md phd is chief of the melanoma and immunotherapeutics service at memorial sloan kettering cancer center msk an associate director of the ludwig center for cancer immunotherapy at msk an associate member of ludwig cancer research and holds the lloyd j oldvirginia and daniel k ludwig chair in clinical investigation at msk he is director of the criludwig cancer vaccine collaborative trials network and is an associate director of the cri scientific advisory council he is also the codirector of the swim across america laboratory at msk one of the foremost immunotherapy and melanoma research groups in the country dr wolchok graduated from new york university school of medicine and completed a residency at memorial sloan kettering cancer center dr wolchok has been an advisor to syndax since july  dr wolchok has been a leader in the preclinical and early clinical development of novel immunologic therapies and was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma he is principal investigator of numerous ongoing clinical trials at msk in the area of immunotherapy dr wolchok has been recognized for his momentous career throughout the years and has received several of awards including the melanoma research foundation – humanitarian award in  the melanoma international foundation’s doctor of the year award in  and the live love laugh foundation and was named the virginia and daniel k ludwig chair for clinical investigation in  pipeline  syndax home about us back about us leadership board of directors scientific advisory board vision mission and values science back pipeline entinostat clinical trials publications access to investigational therapies investors collaboration career opportunities contact us contact us pipelinepipeline entinostat clinical trials publications access to investigational therapies     syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications entinostat entinostat is our oral small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells potentially enhancing the body’s immune response to tumors the favorable safety profile of entinostat has been demonstrated in clinical trials in more than  cancer patients sndx sndx is a high affinity antibody targeting the colony stimulating factor  receptor csfr it has shown evidence of antitumor and antimetastatic efficacy through its ability to limit the number and activity of immunosuppressive cells such as tumor associated macrophages   entinostat clinical trials publications collaboration sndx key statistics  syndax pharmaceuticals inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close syndax pharmaceuticals inc nasdaq sndx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus syndax pharmaceuticals inc after hours  quotes are delayed by  min jul    pm sndx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description syndax pharmaceuticals inc operates as a clinical stage biopharmaceutical company which engages in the development of cancer therapies it focuses on the development and commercialization of its lead product candidate entinostat an epigenetic therapy for treatmentresistant cancers the company syndax pharmaceuticals inc operates as a clinical stage biopharmaceutical company which engages in the development of cancer therapies it focuses on the development and commercialization of its lead product candidate entinostat an epigenetic therapy for treatmentresistant cancers the company was founded by richard a heyman eckard weber peter ordentlich ronald m evans and michael downes on october   and is headquartered in waltham ma valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr briggs w morrison   chief executive officer  director mr michael a metzger   president  chief operating officer mr richard p shea   chief financial officer  treasurer dr peter ordentlich   chief scientific officer dr michael l meyers   chief medical officer  senior vice president insider actions – purchase – sale  – number of transactions  sponsored topics see a problem let us know legal help syndax pharmaceuticals inc  sndx  stock price today  zacks sndx is down  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more syndax pharmaceuticals inc sndx delayed data from nsdq  usd     updated jul    pm et aftermarket     pm et add to portfolio zacks rank buy          style scores f value  d growth  f momentum  f vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for sndx all zacks’ analyst reports news for sndx zacks news for sndx other news for sndx whats in the cards for merrimack mack in q earnings am est zacks intrexon xon will the stock pull a surprise in q earnings pm est zacks sndx what are zacks experts saying now zacks private portfolio services agenus agen whats ahead for the stock in q earnings pm est zacks puma biotechnology pbyi q earnings whats in the cards am est zacks arena pharmaceuticals arna q earnings what to expect am est zacks more zacks news for sndx syndax locks in to tumor escape am est seeking alpha commit to buy syndax pharmaceuticals at  earn  annualized using options am est stock options channel syndax prices public offering of common stock am est gurufocus syndax pharmaceuticals  as it launches m share offering am est seeking alpha syndax announces proposed public offering of common stock am est gurufocus more other news for sndx premium research for sndx zacks rank buy  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  d growth  f momentum  f vgm earnings esp  research report for sndx snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank syndax pharmaceuticals inc sndx bioverativ inc bivv cellectis sa clls enzo biochem inc enz exelixis inc exel vertex pharmaceuticals incorporated vrtx aveo pharmaceuticals inc aveo see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary syndax pharmaceuticals inc is a biopharmaceutical company which focused on the development and commercialization of entinostat an epigenetic therapy for treatmentresistant cancers the companys product pipeline includes encore  encore  j nci nci e nci and nci which are in clinical trial stage syndax pharmaceuticals inc is based in waltham united states